← Leaderboards
Terry J. Fry
University Of Colorado Denver
$3,169,598
Attributed
$6,339,195
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,339,195 · 2
By mechanism
U01$3,950,741 · 1
R01$2,388,454 · 1
Top collaborators
- Patricia A Ernst5 shared
- Sarah Kathleen Tasian1 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Elizabeth J Shpall$12,617,686
- Taras Lyubchenko$1,011,250
- Matthew Witkowski$1,035,186
- Hae J Park$153,008
- Francesca Alvarez Calderon$142,364
Others in their field
Other Emerging Leaders on “Refractory”
- John Damon Chodera · Sloan-Kettering Inst Can Research$13,706,419
- Leonard Freedman · Leidos Biomedical Research, Inc.$9,392,562
- Christopher B. Granger · Duke University$9,106,303
- Crystal Mackall · Children'S Hosp Of Philadelphia$8,791,590
- Steven Armen Boyd · Venatorx Pharmaceuticals, Inc.$6,328,779
- Patricio Sepulveda · Amplo Biotechnology, Inc.$5,506,739
Research focus
RefractoryDisease RemissionGeneticRelapseIn VivoLeukemiaMll GeneResistanceCd19 GeneImmunotherapeutic AgentEpigenetic ProcessB-Cell Acute Lymphoblastic LeukemiaAntigensHeterogeneityCellsImmunotherapyDesignCurative TreatmentsChimeric Antigen ReceptorCytokineB Lymphoid MalignancyCytokine SignalingB-LymphocytesChildhood
Grant awards (6)
Escape from CAR T surveillance through lineage plasticity$557,374
R01 · FY2025 · CA
Escape from CAR T surveillance through lineage plasticity$535,637
R01 · FY2024 · CA
Defining and predicting features of lineage-switch potential in KMT2A-r B-ALL using barcoding$156,000
R01 · FY2024 · CA
Escape from CAR T surveillance through lineage plasticity$560,773
R01 · FY2023 · CA
Escape from CAR T surveillance through lineage plasticity$578,670
R01 · FY2022 · CA
Multispecific targeting incorporating cytokine receptor pathways in high risk pediatric acute leukemias to improve durability of adoptive cell therapy-induced remissions$3,950,741
U01 · FY2018 · CA · contact PI